This is with reference to unrated unlisted redeemable non-convertible debentures under Series 1A Series 1B and Series 3 NCDs (NCDs) issued by Companys material wholly owned subsidiary company viz. Panacea Biotec Pharma Limited (PBPL) to India Resurgence Fund - Scheme 1 India Resurgence Fund - Scheme 2 and Piramal Enterprises Limited (Debenture Holders) and outstanding as on March 03 2022.We also draw your attention to our earlier letter dated March 01 2022 intimating about sale of domestic pharmaceutical formulation brands in India and Nepal by PBPL.In regard to the above we are pleased to inform that PBPL has fully redeemed the entire outstanding NCDs aggregating Rs.754.44 Crores together with redemption premium of Rs.343.63 Crores out of the funds received by it in consideration of the above referred transaction. As a result of this PBPL has now become a debt free company. This is for your kind information and record please.
Panacea Biotec: Intimation Of Redemption Of 79 800 Unrated Unlisted Redeemable Non-Convertible Debentures (Ncds) Issued By Material Subsidiary Viz. Panacea Biotec Pharma Limited
March 4, 2022
Download PDF
Panacea Biotec